<SEC-DOCUMENT>0000876661-25-000339.txt : 20250515
<SEC-HEADER>0000876661-25-000339.hdr.sgml : 20250515
<ACCEPTANCE-DATETIME>20250515104830
ACCESSION NUMBER:		0000876661-25-000339
CONFORMED SUBMISSION TYPE:	25-NSE
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250515
DATE AS OF CHANGE:		20250515
EFFECTIVENESS DATE:		20250515

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GSK plc
		CENTRAL INDEX KEY:			0001131399
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			X0

	FILING VALUES:
		FORM TYPE:		25-NSE
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15170
		FILM NUMBER:		25949911

	BUSINESS ADDRESS:	
		STREET 1:		79 NEW OXFORD STREET
		CITY:			LONDON
		STATE:			X0
		ZIP:			WC1A 1DG
		BUSINESS PHONE:		011442080475000

	MAIL ADDRESS:	
		STREET 1:		79 NEW OXFORD STREET
		CITY:			LONDON
		STATE:			X0
		ZIP:			WC1A 1DG

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GSK PLC
		DATE OF NAME CHANGE:	20220516

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GLAXOSMITHKLINE PLC
		DATE OF NAME CHANGE:	20010105

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEW YORK STOCK EXCHANGE LLC
		CENTRAL INDEX KEY:			0000876661
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			NY

	FILING VALUES:
		FORM TYPE:		25-NSE

	BUSINESS ADDRESS:	
		STREET 1:		11 WALL STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10005
		BUSINESS PHONE:		212-656-2060

	MAIL ADDRESS:	
		STREET 1:		11 WALL STREET
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NEW YORK STOCK EXCHANGE INC
		DATE OF NAME CHANGE:	19910628
</SEC-HEADER>
<DOCUMENT>
<TYPE>25-NSE
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<notificationOfRemoval>

    <schemaVersion>X0203</schemaVersion>

    <exchange>
        <cik>0000876661</cik>
        <entityName>NEW YORK STOCK EXCHANGE LLC</entityName>
    </exchange>

    <issuer>
        <cik>0001131399</cik>
        <entityName>GSK plc</entityName>
        <fileNumber>001-15170</fileNumber>
        <address>
            <street1>79 New Oxford Street</street1>
            <city>London</city>
            <stateOrCountryCode></stateOrCountryCode>
            <stateOrCountry></stateOrCountry>
            <zipCode>WC1A 1DG</zipCode>
        </address>
        <telephoneNumber>+44 20 8047 5000</telephoneNumber>
    </issuer>

    <descriptionClassSecurity>Gurrantor of 3.625% Notes due May 15, 2025</descriptionClassSecurity>

    <ruleProvision>17 CFR 240.12d2-2(a)(2)</ruleProvision>

    <signatureData>
        <signatureName>Tyler Mastronardi</signatureName>
        <signatureTitle>Analyst, Regulation</signatureTitle>
        <signatureDate>2025-05-15</signatureDate>
    </signatureData>
</notificationOfRemoval>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.25
<SEQUENCE>2
<FILENAME>ruleprovisionnotice.htm
<TEXT>
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES

The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on May 27, 2025, pursuant to the provisions of Rule 12d2-2 (a).

[ X ] 17 CFR 240.12d2-2(a)(2) That the entire class of this security was redeemed or paid at maturity or retirement on May 15, 2025.

The Exchange also notifies the Securities and Exchange Commission that as a result of the above indicated conditions this security was suspended from trading on May 15, 2025.
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
